PMID- 22137560
OWN - NLM
STAT- MEDLINE
DCOM- 20120906
LR  - 20141120
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 76
IP  - 3
DP  - 2012 Jun
TI  - FATS expression is associated with cisplatin sensitivity in non small cell lung 
      cancer.
PG  - 416-22
LID - 10.1016/j.lungcan.2011.11.009 [doi]
AB  - BACKGROUND: Although the survival benefit of cisplatin-based adjuvant 
      chemotherapy has been proven for patients with non small cell lung cancer 
      (NSCLC), the resistance to cisplatin and its dose-dependent side effects remain a 
      challenge. Improvement in survival and reduction of side effects require a 
      biomarker capable of defining the response to cisplatin treatments in patients 
      with NSCLC. FATS is a newly identified tumor suppressor involved in DNA 
      damage-induced carcinogenesis. In this study, we investigated whether the 
      quantified mRNA expression of FATS can predict cisplatin sensitivity in NSCLC. 
      METHODS: The expression level of FATS mRNA in tumor samples from patients 
      receiving an initial diagnosis of NSCLC (n=89) was determined by quantitative 
      real-time reverse transcription PCR. The histological characteristics of patients 
      were retrospectively reviewed. Cisplatin-induced apoptosis in NSCLC cells was 
      evaluated by flow cytometry after Annexin V staining. RESULTS: The mRNA level of 
      FATS was significantly downregulated in NSCLC samples compared with normal 
      tissues from the same patient (P=0.001). Low level of FATS mRNA expression was 
      correlated with poor overall survival in NSCLC (P=0.030). For those NSCLC 
      patients receiving cisplatin-based chemotherapy, the overall survival was 
      significantly longer in FATS-high subgroup than that in FATS-low subgroup 
      (P=0.038). Multivariate analysis revealed the independent value of FATS mRNA in 
      predicting the overall survival for NSCLC patients receiving cisplatin-based 
      chemotherapy. Furthermore, enhanced expression of FATS significantly sensitized 
      NSCLC cells to cisplatin-induced apoptosis. CONCLUSION: The relatively high 
      expression of FATS mRNA provides a new biomarker for a good outcome in patients 
      receiving cisplatin-based chemotherapy.
CI  - Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
FAU - Tian, Yin
AU  - Tian Y
AD  - Department of Biochemistry and Molecular Biology, Tianjin Medical University 
      Cancer Institute and Hospital, Tianjin, China.
FAU - Zhang, Jun
AU  - Zhang J
FAU - Yan, Shuangshuang
AU  - Yan S
FAU - Qiu, Li
AU  - Qiu L
FAU - Li, Zheng
AU  - Li Z
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111202
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Antineoplastic Agents)
RN  - 0 (C10orf90 protein, human)
RN  - 0 (Cytoskeletal Proteins)
RN  - 0 (Proteins)
RN  - 0 (RNA, Messenger)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/*genetics/mortality/pathology
MH  - Cell Line, Tumor
MH  - Cisplatin/*therapeutic use
MH  - Cytoskeletal Proteins
MH  - Female
MH  - Gene Expression
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/*genetics/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Proteins/*genetics
MH  - RNA, Messenger/metabolism
MH  - ROC Curve
MH  - Retrospective Studies
MH  - Survival Analysis
EDAT- 2011/12/06 06:00
MHDA- 2012/09/07 06:00
CRDT- 2011/12/06 06:00
PHST- 2011/07/22 00:00 [received]
PHST- 2011/09/26 00:00 [revised]
PHST- 2011/11/07 00:00 [accepted]
PHST- 2011/12/06 06:00 [entrez]
PHST- 2011/12/06 06:00 [pubmed]
PHST- 2012/09/07 06:00 [medline]
AID - S0169-5002(11)00583-6 [pii]
AID - 10.1016/j.lungcan.2011.11.009 [doi]
PST - ppublish
SO  - Lung Cancer. 2012 Jun;76(3):416-22. doi: 10.1016/j.lungcan.2011.11.009. Epub 2011 
      Dec 2.